Gradient-echo magnetic resonance imaging study of pancreatic iron overload in young Egyptian beta-thalassemia major patients and effect of splenectomy.
BACKGROUND
Thalassemic patients suffer from diabetes mellitus secondary to hemosiderosis.


OBJECTIVE
The study aimed to evaluate pancreatic iron overload by T2*-weighted Gradient-echo magnetic resonance imaging (MRI) in young beta-thalassemia major patients and to correlate it with glucose disturbances, hepatic hemosiderosis, serum ferritin and splenectomy.


METHODS
Forty thalassemic patients (20 non diabetic, 10 diabetic, and 10 with impaired glucose tolerance) were recruited from Pediatric Hematology Clinic, in addition to 20 healthy controls. All patients underwent clinical assessment and laboratory investigations included complete blood count, liver function tests, serum ferritin and oral glucose tolerance test (OGTT). A T2*-weighted gradient-echo sequence MRI was performed with 1.5 T scanner and signal intensity ratio (SIR) of the liver and the pancreas to noise were calculated.


RESULTS
Significant reduction in signal intensity ratio (SIR) of the liver and the pancreas was shown in thalassemic patients compared to controls (P < 0.0001), Thalassemic patients with abnormal glucose tolerance; including diabetics and thalassemics with impaired glucose tolerance; displayed a higher degree of pancreatic and hepatic siderosis compared to thalassemics with normal glucose tolerance or controls (P < 0.001, P < 0.0001). Splenectomized thalassemic patients had significantly lower SIR of pancreas compared to non splenectomized patients (P < 0.05). A strong correlation was present between hepatic and pancreatic siderosis in studied patients (P < 0.001).


CONCLUSIONS
pancreatic siderosis can be detected by T2* gradient-echo MRI since childhood in thalassemic patients, and is more evident in patients with abnormal glucose tolerance. After splenectomy, iron deposition may be accelerated in the pancreas. Follow up of thalassemic patients using pancreatic MRI together with intensive chelation therapy may help to prevent the development of overt diabetes.
Matter
Randa M
RM
Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt. randa_matar@yahoo.com
Allam
Khalid E
KE
Sadony
Amany M
AM
Blood. 2009 Nov 5;114(19):4021-6
19726718
Eur Radiol. 2007 Dec;17(12):3025-30
17549485
Eur J Pediatr. 2003 Mar;162(3):139-146
12655415
AJR Am J Roentgenol. 1999 Jul;173(1):187-92
10397124
J Magn Reson Imaging. 2006 Feb;23(2):163-70
16374880
Br J Haematol. 2006 Aug;134(4):438-44
16822284
Curr Opin Hematol. 2007 May;14(3):183-90
17414205
Ann N Y Acad Sci. 1990;612:293-310
2291557
J Magn Reson Imaging. 2009 Apr;29(4):853-9
19306409
Lancet. 2004 Jan 31;363(9406):357-62
15070565
Hemoglobin. 2009;33(2):101-8
19373585
Med J Malaysia. 2008 Jun;63(2):109-12
18942294
Haematologica. 2008 Jan;93(1):116-9
18166794
J Magn Reson Imaging. 2003 May;17(5):589-92
12720269
Pancreas. 1993 Mar;8(2):176-80
8460093
Diabetes Metab. 2001 Apr;27(2 Pt 1):149-54
11353881
Br J Haematol. 2004 Feb;124(3):385-90
14717788
Eur Radiol. 2003 Jan;13(1):12-6
12541105
Eur J Haematol. 2009 May;82(5):388-92
19141120
J Pediatr Endocrinol Metab. 2000 Mar;13(3):303-6
10714756
Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:158-69
19337172
Radiology. 1994 Nov;193(2):533-8
7972774
J Pediatr Hematol Oncol. 2006 May;28(5):311-5
16772883
AJR Am J Roentgenol. 1997 May;168(5):1205-8
9129412
Radiology. 1999 Jul;212(1):227-34
10405746
Pediatr Diabetes. 2004 Sep;5(3):126-32
15450007
Pediatr Blood Cancer. 2009 Dec;53(6):1054-9
19618454
Eur Radiol. 2007 Jun;17(6):1535-43
17149622
Diabetes Care. 2001 May;24(5):850-4
11347742
Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:249-55
16462705
Haematologica. 2008 May;93(5):784-6
18450735
Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:267-71
16462709
Hong Kong Med J. 2002 Aug;8(4):255-60
12167729
J Magn Reson Imaging. 2009 Feb;29(2):357-64
19161188